25.75MMarket Cap-452P/E (TTM)
2.8000High2.7200Low1.76KVolume2.8000Open2.7650Pre Close4.85KTurnover0.03%Turnover RatioLossP/E (Static)9.23MShares10.500052wk High0.56P/B16.71MFloat Cap2.160052wk Low--Dividend TTM5.99MShs Float129.0000Historical High--Div YieldTTM2.89%Amplitude2.1600Historical Low2.7640Avg Price1Lot Size
SAB Biotherapeutics Stock Forum
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
SAB-142 has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is progressing to enroll patients with type 1 diabetes in the last cohort of the study.
Target dose of SAB-142 2.5mg/kg completed with no observation of serum sickness.
SAB-142 remains on track for a topline Phase 1 data readout by the end of the ye...
FDA Provides Clearance to Ind Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
NEWS
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
SAB Biotherapeutics (Nasdaq: SABS) announced that the FDA has cleared its IND application for SAB-142, a type 1 diabetes therapy, to proceed to a Phase 1 clinical trial in the US.
SAB-142, a human anti-thymocyte immunoglobulin (hIgG), aims to delay the onset or progression of type 1 diabetes. The ongoing HUMAN trial will assess the safety, tolerability, pharmac...
$Femto Technologies (BCAN.US)$ $SAB Biotherapeutics (SABS.US)$ $Macatawa Bank (MCBC.US)$ $Dragonfly Energy (DFLI.US)$ $My Size (MYSZ.US)$ $SoundHound AI (SOUN.US)$ $ARK 21Shares Bitcoin ETF (ARKB.US)$
📊⚡️📊 #stock_drift24
⭐️just a watchlist, not financisl advice⭐️
NEWS
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics, Inc. (Nasdaq: SABS) provides an update on the SAB-142 trial, reporting completion of dosing the third cohort with no observation of serum sickness. The Phase 1 clinical trial aims to investigate safety, tolerability, pharmacokinetics, and immunogenicity of SAB-142, a human anti-thymocyte immunoglobulin for delaying the onset or progression of type 1 diabetes (T1D).
MIAMI BEACH, Fla., April ...
$Liquidia (LQDA.US)$ Also has FDA approval in 15 days. Has no resistance. Will make a 5 year high after it breaks 22.00.
$Trio Petroleum (TPET.US)$ Announced news on Thursday. The last time it released similar news it took it a couple of days before it got going. After .40 it will run to .62 for 100% profit.
$Sharps Technology (STSS.US)$ Ran up i...
No comment yet